A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.
Kunal B DesaiLandon C BrownWei WeiMatthew D TuckerChester KaoEmily KinseyBrian RiniKathryn E BeckermannTian ZhangMoshe C OrnsteinPublished in: Targeted oncology (2021)
RCC patients with ≥ 1 BM who received I + N therapy had a relatively low response rate, PFS, and OS. Strategies to improve outcomes in this subset of patients are needed.